Why Does Jefferies Expect a Mixed Outlook for Indian Pharma in 2026?
Jefferies’ Sector View
Jefferies expects FY2026 to be a mixed year for the Indian pharmaceutical sector. While demand visibility remains intact, pricing pressures, regulatory scrutiny, and execution dispersion are likely to create divergence across companies.
Against this backdrop, the brokerage highlights Sai LifeSciences and Divi’s Laboratories as preferred picks due to their strong execution track records and relatively healthier growth visibility.
Key Pharma Themes for 2026
🔹 Uneven growth across formulations and APIs.
🔹 Execution quality becomes key differentiator.
🔹 Regulatory overhang persists selectively.
🔹 Balance sheet strength matters more.
Jefferies believes companies with scale, complex chemistry capabilities, and regulated market exposure will continue to outperform peers in a challenging environment.
Investors tracking sector rotation often use disciplined approaches such as a Nifty Tips framework to stay aligned with execution-led winners.
Investor Takeaway
Derivative Pro & Nifty Expert Gulshan Khera, CFP®, believes that Indian pharma is transitioning into a phase where stock selection matters more than sector calls. Companies with proven execution, regulatory discipline, and capital efficiency are likely to command valuation premiums. More sector insights are available at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice.
Written by Indian-Share-Tips.com, which is a SEBI Registered Advisory Services
